Perfil del autor: Argüelles Arias, Federico
Datos institucionales
| Nombre | Argüelles Arias, Federico |
| Departamento | Medicina |
| Área de conocimiento | Medicina |
| Categoría profesional | Profesor Contratado Doctor (Plaza Vinc.) |
| Correo electrónico | Solicitar |
 |
|
Estadísticas
-
Nº publicaciones
32
-
Nº visitas
3739
-
Nº descargas
8382
| Publicaciones |
|---|
Tesis Doctoral
 ¿Influye el genotipo HLA-DQA1*05 en la respuesta frente a los fármacos anti-TNF y nuevos biológicos ustekinumab y vedolizumab?
(2024)
El éxito de las estrategias con fármacos anti-TNF en el tratamiento de la enfermedad inflamatoria intestinal (EII) se ve ... |
Artículo
 Performance of a Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA
(Springer, 2023)
Background Therapeutic drug monitoring of infliximab levels in patients with inflammatory bowel disease (IBD) optimizes ... |
Tesis Doctoral
Evaluación de la variabilidad interobservador de las escalas endoscópicas de actividad en pacientes con enfermedad de Crohn y su correlación con índices clínicos y biomarcadores
(2023)
Introducción: La evaluación de la actividad endoscópica en pacientes con enfermedad de Crohn (EC) es de gran relevancia ... |
Tesis Doctoral
Pseudopólipos inflamatorios en pacientes con enfermedad inflamatoria intestinal: correlación entre hallazgos macroscópicos y microscópicos, clasificación histológica e implicaciones clínicas
(2023)
Los pseudopólipos inflamatorios (PPII) son lesiones no neoplásicas que aparecen como consecuencia de repetidos ciclos de ... |
Artículo
Clinical Utility of Urinary Gluten Immunogenic Peptides in the Follow-up of Patients with Coeliac Disease
(Wiley-Blackwell, 2023)
Background: Gluten-free diet (GFD) is the only treatment for patients with coeliac disease (CD). and its compliance should ... |
Artículo
Effectiveness and safety of ustekinumab in bio-naive Crohn's disease patients: a multicentre observational retrospective study
(SAGE Publishing, 2023)
Background: Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn’s disease (CD). However, ... |
Artículo
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing
(SAGE Publications, 2023)
Background: Ustekinumab (UST) is indicated for the treatment of Crohn's disease (CD) and Ulcerative Colitis (UC). Despite ... |
Artículo
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
(MDPI, 2022)
Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with ... |
Artículo
Long-term real-world effectiveness and safety of ustekinumab in Crohn's disease patients: the SUSTAIN study.
(Oxford University Press, 2022)
Background: Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety ... |
Artículo
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
(Frontiers Media S.A., 2022)
Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and ... |
Artículo
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
(MDPI, 2022)
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for ... |
Artículo
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: results from the VERNE study
(Elsevier, 2022)
Background Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases ... |
Artículo
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
(MDPI, 2022)
Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the ... |
Artículo
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
(Sage Publishing, 2022)
Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in ... |
Artículo
Native Chilean Berries Preservation and In Vitro Studies of a Polyphenol Highly Antioxidant Extract from Maqui as a Potential Agent against Inflammatory Diseases
(MDPI, 2021)
The best conservation method for native Chilean berries has been investigated in combination with an implemented large-scale ... |
Tesis Doctoral
Monitorización de niveles de Infliximab y anticuerpos Anti-Infliximab en pacientes con enfermedad inflamatoria intestinal en práctica clínica
(2021)
Introducción Infliximab (IFX) es un fármaco anti-TNF que consigue una buena tasa de respuesta y remisión en muchos pacientes ... |
Artículo
Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome
(SAGE Publishing, 2021)
Background: Irritable bowel syndrome with diarrhoea (IBS-D) is a frequent problem associated with a significant socioeconomic ... |
Artículo
Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity
(Thieme, 2021)
Background and study aims: Endoscopy plays an essential role in managing patients with ulcerative colitis (UC), as it ... |
Artículo
Perspectiva de los pacientes con enfermedad inflamatoria intestinal durante la pandemia COVID-19: resultados Encuesta ACCU
(Arán Ediciones, S.L., 2021)
Introducción y objetivos: la pandemia por el SARS-CoV-2 ha obligado a un cambio sustancial en la atención a los pacien- tes ... |
Tesis Doctoral
Evaluación de la variabilidad interobservador de los scores endoscópicos que valoran la actividad de la enfermedad en pacientes con colitis ulcerosa
(2020)
Objetivos: el objetivo principal del estudio fue evaluar la variabilidad interobservador para el Índice de Mayo Endoscópico ... |
Artículo
Small Bowel Enteroscopy-A Joint Clinical Guideline from the Spanish and Portuguese Small Bowel Study Groups
(Karger Publishers, 2020)
The present evidence-based guidelines are focused on the use of device-assisted enteroscopy in the management of small-bowel ... |
Artículo
Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study
(BMJ Publishing Group, 2020)
Objective To evaluate the impact of comorbidities and extraintestinal manifestations of inflammatory bowel disease on the ... |
Artículo
Polyphenolic Maqui Extract as a Potential Nutraceutical to Treat TNBS-Induced Crohn' s Disease by the Regulation of Antioxidant and Anti-Inflammatory Pathways
(MDPI, 2020)
Nutraceuticals include a wide variety of bioactive compounds, such as polyphenols, which have been highlighted for their ... |
Artículo
Polymeric nanoparticles for drug delivery: Recent developments and future prospects
(Multidisciplinary Digital Publishing Institute (MDPI), 2020)
The complexity of some diseases—as well as the inherent toxicity of certain drugs—has led to an increasing interest in the ... |
Artículo
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
(Original Research, 2019)
Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated ... |
Tesis Doctoral
Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal.
(2018)
Introducción: las terapias biológicas, particularmente agentes anti-TNF alfa, han revolucionado el enfoque terapéutico de ... |
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ... |
Tesis Doctoral
Estudio comparativo, prospectivo y randomizado de tres preparaciones para el estudio del colon mediante cápsula endoscópica de colón
(2016)
Introducción y objetivos. El cáncer colorrectal (CCR) representa en conjunto el 10% de todos los tumores a nivel mundial. ... |
| Artículo |
| Artículo |
| Artículo |
| Artículo |